Showing results (311-320 of 382) with videos related to

Sort By:
Pageof 39
Cancer Cell|May 15, 2014
Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasiaFlorencia McAllister, Jennifer M Bailey, Janivette Alsina, et al.
International Journal of Cancer|September 25, 2018
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastomaSarah Harris-Bookman, Dimitrios Mathios, Allison M Martin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 18, 2009
Tc17 CD8 T cells: functional plasticity and subset diversityHung-Rong Yen, Timothy J Harris, Satoshi Wada, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomasJing Zeng, Alfred P See, Jillian Phallen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
Cancer Cell|April 28, 2023
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulatorsAleksandar Obradovic, Casey Ager, Mikko Turunen, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.
Pageof 39